Výsledky vyhledávání - "Jessy Delaye"

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 125, pp.31-37. ⟨10.1016/j.ejca.2019.10.028⟩

Background Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib (P) monotherapy. Currently, no combination therapy is better than monotherapy. LM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0107c14f51538cc391d83fa56795ad4
https://hal.archives-ouvertes.fr/hal-02429038

Zobrazit plný text záznamu

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

Autor: Marie-Cécile Le Deley, Sophie Piperno-Neumann, Laurence Brugières, Gwénaël Le Teuff, Lisa V. Hampson, Jessy Delaye, Caroline Brard, Nathalie Gaspar

Publikováno v: BMJ Open

IntroductionThe controversial results on the mifamurtide efficacy associated with chemotherapy, issued from the American INT-0133-study, in localised osteosarcomas, and the underpowered analysis performed separately in metastatic patients, should be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::935db28cf34db5b0fafbb3be98dceefb
https://pubmed.ncbi.nlm.nih.gov/31110092

Zobrazit plný text záznamu

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Autor: Antoine Italiano, Vincent Vidal, Elsa Kalbacher, Olivier Collard, Olivier Mir, Camille Schiffler, Christine Chevreau, Corinne Bouvier, Jessy Delaye, Florence Duffaud, Pascaline Boudou-Rouquette, Emmanuelle Bompas, Jean-Yves Blay, Esma Saada, Sophie Piperno-Neumann, Nicolas Isambert, Corinne Delcambre, Sylvie Chabaud, Nicolas Penel

Publikováno v: The Lancet. Oncology. 20(1)

Summary Background Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f002dca7b0678be05240e64d7bc55a11
https://pubmed.ncbi.nlm.nih.gov/30477938

Zobrazit plný text záznamu

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩
European Journal of Cancer, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩

Background In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum). In France, the standard preoperative chemotherapy for children/adolescents combines M and etoposide-ifosf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b208da312db42032cd8ff388934b4d64
https://www.hal.inserm.fr/inserm-01667245

Zobrazit plný text záznamu

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group

Autor: Laurence Digue, Frederic Rolland, Aurélie Guyennon, Sylvie Zanetta, Jérôme Fayette, Didier Cupissol, Christophe Le Tourneau, Jessy Delaye, Isabelle Jallut, Audrey Lardy-Cleaud, Laurence Bozec Lemoal, Valérie Costes, Sophie Couchon-Thaunat, Joël Guigay, Sylvie Chabaud, Anne-Françoise Dillies, Christian Borel, Caroline Even, Lionnel Geoffrois

Publikováno v: Journal of Clinical Oncology. 37:6083-6083

6083 Background: SGCHN are rare tumors including adenoid cystic carcinoma (ACC) and non-ACC, with no standard systemic treatment for R/M pts. We evaluated N monotherapy in R/M SGCHN pts. Methods: R/M SGCHN pts (ACC or non-ACC) not eligible to local t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cd71d22192da552a031647d29559ac2
https://doi.org/10.1200/jco.2019.37.15_suppl.6083

Zobrazit plný text záznamu

A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group

Publikováno v: Journal of Clinical Oncology. 37:6032-6032

6032 Background: In the randomized phase III Study CA209141, Nivolumab (N) demonstrated significant overall survival (OS) benefit with favorable safety profile for platinum refractory R/M SCCHN and is now approved for these patients (pts). The object

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5aad3d1feb8cbab2ad2c2975ff4de6e5
https://doi.org/10.1200/jco.2019.37.15_suppl.6032

Zobrazit plný text záznamu

Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer

Publikováno v: Journal of Clinical Oncology. 36:11504-11504

11504Background: Oral multikinase inhibitor REG has shown activity in GIST and non-adipocytic soft tissue sarcomas. We designed REGOBONE as a non-comparative phase II, double-blind, PL-controlled t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b566adecfd9cef6bcda7d6dc0bbfe817
https://doi.org/10.1200/jco.2018.36.15_suppl.11504

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání